US panel knocks efficacy of Arpida's iclaprim for skin infections
This article was originally published in Scrip
Executive Summary
The US FDA's outside advisors soundly recommended against approval of Arpida's iclaprim on November 20th, saying the company failed to establish that the antibacterial's efficacy was non-inferior to linezolid in treating complicated skin and skin structure infections (cSSSI).